Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
Dipartimento di Medicina Interna, Malattie Cardiovascolari e Nefrourologiche, Policlinico Universitario Paolo Giaccone Via del Vespro, 14 90127 Palermo.
The coagulation cascade, and particularly thrombin, plays a very important role in arterial and venous thrombosis. Thereby, it is clear that thrombin inactivation is an optimal strategy for thrombotic disease prevention and treatment. The direct thrombin inhibitors are a new class of anticoagulant drugs directly binding thrombin and blocking its interaction with fibrinogen. The group of direct thrombin inhibitors includes recombinant hirudin (lepirudin and desirudin), bivalirudin, melagatran and its oral precursor, ximelagatran, argotraban and dabigatran. These drugs have several advantages compared to other anticoagulant drugs, and the particular pharmacokinetic properties of some of them could be very important for future management of thromboembolic prophylaxis. The efficacy and safety of these new drugs are evaluated in several clinical trials; however today only few clinical indications are available for the majority of them.
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on